Anomalous binding of [3H]N-methylscopolamine to rat brain muscarinic receptors

Daily variation of muscarinic receptors in visual cortex but not suprachiasmatic nucleus of Syrian hamsters

Intraventricular administration of carbachol can induce phase shifts in wheel-running activity in rodents, which depend on circadian phase and are mediated via muscarinic cholinergic receptors in Syrian hamsters. We studied the circadian variation in binding of [3H]-N-methylscopolamine ([3H]NMS), a hydrophilic muscarinic receptor antagonist, in micropunches obtained from the anterior hypothalamus and occipital cortex of Syrian hamsters housed in a 14:10 light:dark cycle. Binding sites were characterized on cells contained within 1 mm punches (obtained from slices 300 microm thick), using a method to selectively detect cell surface (functional) receptors. Atropine sulphate was used to determine nonspecific binding. Cortex showed a significant daily rhythm in [3H]NMS binding with a peak occurring late in the light phase and a trough at lights on, while the hypothalamus showed no detectable rhythm. Following suprachiasmatic nucleus (SCN) ablation or maintenance in constant darkness, the rhythm in the cortex was abolished. These findings suggest that photic information conveyed via the SCN is responsible for the receptor binding rhythm in the cortex. Autoradiographic studies ([3H]NMS; 2 nM, 3 weeks exposure) clearly revealed both M1 and M2 subtypes of muscarinic receptors in the region of the SCN and the visual cortex.

Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at cholinoceptor sites

The binding of the bisquaternary muscarine receptor antagonist heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)-ammonium bromide (C7/3-phth) was investigated at a number of cholinergic binding sites using (-)-[3H]nicotine, [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate ([3H]QNB) in both central and peripheral tissues. C7/3-phth displayed an affinity for muscarine M2 receptors in rat atria (70.1 nM) which was 1.6-fold greater than for putative M4 receptors in rabbit lung, and 4- to 5-fold greater than for M1 receptors in rat cerebral cortex. Its affinity for nicotine receptors in the cortex was low, being 808-fold lower than its affinity for the M2 receptor. Although the displacement of (-)-[3H]nicotine and [3H]pirenzepine binding in rat cortex by C7/3-phth was best described in terms of one-site modelling, low Hill coefficients were observed with C7/3-phth in displacement studies using [3H]QNB in this tissue. The possibility of allosteric interactions or multiple receptor subtype interactions is discussed.

Anomalous binding of [3H]N-methyl-quinuclidinyl benzilate methyl chloride to human lymphocyte muscarinic receptors

Using the muscarinic cholinergic ligand [3H]N-methyl quinuclidinyl benzilate methyl chloride ([3H]NM-QNB), we demonstrated that intact, viable human lymphocytes possess specific muscarinic binding sites. Equilibrium binding studies show that muscarinic acetylcholine receptor are divided into two subtype; high affinity (Ms) and low affinity types (Mw) for the ligand.

Gradient distribution pattern of muscarinic receptors in N1E 115 mouse neuroblastoma cells

The distribution pattern of muscarinic receptors in N1E 115 mouse neuroblastoma cells after linear and non-linear gradient centrifugation was investigated. In untreated cells, at least two forms of the receptors, with different densities, were found.

Mechanism of agonist-induced down-regulation and subsequent recovery of muscarinic acetylcholine receptors in a clonal neuroblastoma x glioma hybrid cell line

The mechanisms of carbachol-induced muscarinic acetylcholine receptor (mAChR) down-regulation, and recovery following carbachol withdrawal, were studied in the neuroblastoma x glioma hybrid NG108-15 cell line by specific ligand binding assays. N-[3H]Methylscopolamine ([3H]NMS) and [3H]quinuclidinyl benzilate ([3H]QNB) were used as the ligands for the cell surface and total cellular mAChRs, respectively. Exposure of cells to 1 mM carbachol for 16 h decreased the specific binding of [3H]NMS and [3H]QNB by approximately 80%. Bacitracin (1-4 mg/ml) and methylamine (1-15 mM), inhibitors of transglutaminase and of endocytosis, prevented agonist-induced loss of surface mAChRs. Pretreatment of cells with the antimicrotubular agents nocodazole (0.1-10 microM) and colchicine (1-10 microM) prevented carbachol-induced loss of [3H]QNB binding, but not that of [3H]NMS binding. These results indicate that agonist-induced mAChR down-regulation occurs by endocytosis, followed by microtubular transport of receptors to their intracellular degradation sites. When carbachol was withdrawn from the culture medium following treatment of cells for 16 h, receptors recovered and were incorporated to the surface membrane. This recovery process was antagonized by monovalent ionophores monensin (0.1 microM) and nigericin (40 nM), which interfere with Golgi complex function. Receptor recovery was also prevented by the antimicrotubular agent nocodazole. Thus, recovery of receptors appears to be mediated via Golgi complex and microtubular transport to the surface membrane.

Muscarinic cholinergic binding sites on rat lymphocytes

Receptors for neurotransmitters in blood cells could serve as useful markers for the same receptors in solid tissues. Muscarinic receptors have been identified in human, rat and mouse lymphocytes by binding of [3H]quinuclidinyl benzilate (3H-QNB); however, the biochemical and pharmacological characterization of such binding sites has not been complete. Spleen lymphocytes were isolated on a histopaque gradient and incubated in Hank's buffer with 3H-QNB. Binding of 3H-QNB was linear with increasing protein concentrations and was saturable. Binding constants were Bmax = 111 +/- 10.5 fmol/10(6) cells, and Kd = 29.7 +/- 3.9 nM (n = 7). An extensive pharmacological analysis of these binding sites indicated that several cholinergic muscarinic drugs were capable of inhibiting 3H-QNB binding. Muscarinic antagonists were more potent than agonists, and lipophilic drugs were more potent than hydrophilic drugs. Several non-cholinergic drugs were also capable of inhibiting 3H-QNB binding; however, they did so also in brain membranes, while a third group of non-cholinergic drugs and neurotransmitters were inactive. Similar results were also obtained in circulating lymphocytes and in lymphocyte membranes. These results suggest that lymphocytes possess muscarinic receptors which share several, although not all, characteristics of the same receptors in brain and other tissues. Measurement of these binding sites could be useful to monitor the status of muscarinic receptors in solid tissues.

The intact human neuroblastoma cell (SH-SY5Y) exhibits high-affinity [3H]pirenzepine binding associated with hydrolysis of phosphatidylinositols

The binding of [3H]pirenzepine to a human neuroblastoma cell line (SH-SY5Y) and its correlation with hydrolysis of phosphatidylinositols were characterized. Specific [3H]pirenzepine binding to intact cells was rapid, reversible, saturable, and of high affinity. Kinetic studies yielded association (k+1) and dissociation (k-1) rate constants of 5.2 +/- 1.4 X 10(6) M-1 min-1 and 1.1 +/- 0.06 X 10(-1) min-1, respectively. Saturation experiments revealed a single class of binding sites (nH = 1.1) for the radioligand with a total binding capacity of 160 +/- 33 fmol/mg protein and an apparent dissociation constant of 13 nM. The specific [3H]pirenzepine binding was inhibited by the presence of selected muscarinic drugs. The order of antagonist potency was atropine sulfate greater than pirenzepine greater than AF-DX 116, with K0.5 of 0.53 nM, 2.2 nM, and 190 nM, respectively. The binding properties of [3H](-)-quinuclidinyl benzilate and its quaternary derivative [3H](-)-methylquinuclidinyl benzilate were also investigated. The muscarinic agonist carbachol stimulated formation of inositol phosphates which could be inhibited by muscarinic antagonists. The inhibition constants of pirenzepine and AF-DX 116 were 11 nM and 190 nM, respectively. In conclusion, we show that the nonclassical muscarinic receptor antagonist [3H]pirenzepine identifies a high-affinity population of muscarinic sites which is associated with hydrolysis of phosphatidylinositols in this human neuroblastoma cell line.

Effects of organophosphates and nerve growth factor on muscarinic receptor binding number in rat pheochromocytoma PC12 cells

Muscarinic receptor binding in PC12 cells is influenced by both nerve growth factor (NGF) and organophosphates. Treatment of PC12 cells with a single dose of NGF (50 ng, 7S NGF/ml) increased [3H]N-methylscopolamine ([3H]-NMS) binding sites approximately two-fold at 48 hr but did not change the Kd for this ligand. Exposure of PC12 cells to soman, 50 microM, decreased [3H]-NMS binding in both undifferentiated and NGF-treated cells; however, decreases in muscarinic binding induced by the organophosphate were only minimal after the first hour after treatment and were maximal at about 24 hr. Other organophosphates including sarin, tabun, and VX as well as the carbamate, pyridostigmine, also reduced [3H]-NMS binding in PC12 cells measured 24-48 hr after treatment. The order of potency of organophosphates in lowering [3H]-NMS binding was soman greater than sarin greater than VX greater than tabun greater than DFP. High amounts of VX (200 microM) but not the other organophosphates inhibited [3H]-NMS binding when added to cells during the course of binding assays. Decreases in muscarinic receptor binding induced by the organophosphates differed markedly from that produced by carbamylcholine, which decreased [3H]-NMS binding maximally 30 min after addition to the cells. Decreases in [3H]-NMS binding produced by carbamylcholine were antagonized by atropine, but reductions in muscarinic binding produced by the organophosphates were not reversed by atropine. Thus, decreases in muscarinic receptor binding induced in PC12 cells by organophosphates occur via a novel mechanism that does not involve agonist-induced receptor desensitization.

Sialic acid is selectively involved in the interaction of agonists with M2 muscarinic acetylcholine receptors

Neuraminidase and slight acid hydrolysis were used to investigate the role of sialic acid residues in the binding of muscarinic agonists and antagonists to membranes from tissues rich in M1 and M2 receptors. Membranes were pretreated with neuraminidase at pH 5 and the binding parameters were determined from competitive experiments with (3H)-quinuclidinylbenzylate. The removal of sialic acid residues reduced the affinity of muscarinic agonists for cerebellum, heart and lung membranes (M2), in contrast to striatum (M1). The affinity of antagonists was not affected. Thus, sialic acid is selectively involved in the interaction of agonists with M2 muscarinic receptors.

Agonist-induced muscarinic acetylcholine receptor down-regulation in intact rat brain cells

Intact brain cells were prepared by dissociating whole adult rat brains without the cerebellum using a sieving technique. It has been found that preincubation of these cells with the muscarinic acetylcholine receptor agonist, carbamylcholine, results in a significant reduction in the specific binding of [3H]N-methylscopolamine to the receptors after the agonist was washed away. This agonist-mediated receptor down-regulation increased with prolongation of the exposure period to the agonist, and a steady state was achieved after 3 h at 37 degrees C. This effect of agonist was concentration-dependent, reaching a 30-35% decline in subsequent ligand binding upon preincubation with 1 mM carbamylcholine for 3 h. Carbamylcholine-induced receptor down-regulation was not apparent when exposure to the agonist was performed at 15 degrees C. In addition, it was abolished when the receptors were blocked by atropine. The decline in [3H]N-methylscopolamine binding induced by agonist was reflected as a significant reduction in the receptor density with no change in receptor affinity, suggesting that 'true' receptor down-regulation takes place. Moreover, when the receptors were labeled with the lipophilic antagonist [3H]quinuclidinyl benzilate instead of the hydrophilic ligand [3H]N-methylscopolamine, the magnitude of the observed receptor down-regulation was significantly lower in case of the former than the latter. This suggests that exposure of intact brain cells to muscarinic agonists might induce a slight degree of accumulation of receptors in intracellular sites before the receptors are actually degraded. These results are discussed in relation to previous findings regarding muscarinic receptor regulation in clonal cell lines.